Now showing items 1-5 of 5
Implementation of the Biosimilar Pathway: Economic and Policy Issues
(Seton Hall Law Review, 2011)
Recent Trends in Brand-Name and Generic Drug Competition
(Journal of Medical Economics, 2013)
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
(Health Aff (Millwood), 2011-11)
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. ...
Data Exclusivity for Biologics
(Nature Reviews Drug Discovery, 2011-01)
Updated trends in US brand-name and generic drug competition
(Journal of Medical Economics, 2016-09)